Molecular biology of myelodysplastic syndromes

Seminars in Oncology

Volumn 38, Issue 5, 2011, Pages 613-620

  Shih, Alan H ^a   Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADDITIONAL SEX COMB LIKE 1; AZACITIDINE; CBL PROTEIN; CYTOKINE RECEPTOR ANTAGONIST; FLT 3 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MEMBRANE PROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN EVI1 MDS1; PROTEIN P53; PROTEIN TET2; RETINOIC ACID; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOPENIA; DISEASE CLASSIFICATION; DNA METHYLATION; EPIGENETICS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTONE MODIFICATION; HUMAN; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL NICHE;

EPIGENESIS, GENETIC; HUMANS; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; STEM CELL NICHE; TRANSCRIPTION FACTORS;

EID: 80053185907     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.013     Document Type: Article

References (56)

1. D. Haase, U. Germing, and J. Schanz New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395 (Pubitemid 351377805)
2. J.D. Growney, H. Shigematsu, and Z. Li Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype Blood 106 2005 494 504 (Pubitemid 40981243)
3. N. Watanabe-Okochi, J. Kitaura, and R. Ono AML1 mutations induced MDS and MDS/AML in a mouse BMT model Blood 111 2008 4297 4308
4. H. Harada, Y. Harada, H. Niimi, T. Kyo, A. Kimura, and T. Inaba High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia Blood 103 2004 2316 2324 (Pubitemid 38326252)
5. D.P. Steensma, R.J. Gibbons, R.A. Mesa, A. Tefferi, and D.R. Higgs Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia Eur J Haematol 74 2005 47 53 (Pubitemid 40143686)
6. W.J. Song, M.G. Sullivan, and R.D. Legare Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia Nat Genet 23 1999 166 175 (Pubitemid 29455388)
7. M. Russell, A. List, and P. Greenberg Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations Blood 84 1994 1243 1248
8. K. Morishita, E. Parganas, and C.L. William Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26 Proc Natl Acad Sci U S A 89 1992 3937 3941
9. J. Soderholm, H. Kobayashi, C. Mathieu, J.D. Rowley, and G. Nucifora The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator Leukemia 11 1997 352 358 (Pubitemid 27120983)
10. S. Buonamici, D. Li, and Y. Chi EVI1 induces myelodysplastic syndrome in mice J Clin Invest 114 2004 713 719 (Pubitemid 39582822)
11. L. Laricchia-Robbio, K. Premanand, C.R. Rinaldi, and G. Nucifora EVI1 impairs myelopoiesis by deregulation of PU.1 function Cancer Res 69 2009 1633 1642
12. H. Yuasa, Y. Oike, and A. Iwama Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression EMBO J 24 2005 1976 1987 (Pubitemid 40896169)
13. S. Goyama, G. Yamamoto, and M. Shimabe Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells Cell Stem Cell 3 2008 207 220
14. Y. Kita-Sasai, S. Horiike, and S. Misawa International Prognostic Scoring System and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome Br J Haematol 115 2001 309 312 (Pubitemid 34203492)
15. J.L. Lai, C. Preudhomme, and M. Zandecki Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations Leukemia 9 1995 370 381
16. M. Constantinidou, G. Chalevelakis, and T. Economopoulos Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value Ann Hematol 74 1997 11 14 (Pubitemid 27050903)
17. D.P. Steensma, G.W. Dewald, and T.L. Lasho The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Blood 106 2005 1207 1209 (Pubitemid 41129580)
18. A. Renneville, B. Quesnel, and A. Charpentier High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis Leukemia 20 2006 2067 2070
19. M. Sanada, T. Suzuki, and L.Y. Shih Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms Nature 460 2009 904 908
20. C. Rathinam, C.B. Thien, W.Y. Langdon, H. Gu, and R.A. Flavell The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells Genes Dev 22 2008 992 997 (Pubitemid 351544238)
21. H. Makishima, H. Cazzolli, and H. Szpurka Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies J Clin Oncol 27 2009 6109 6116
22. L. Shen, H. Kantarjian, and Y. Guo DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J Clin Oncol 28 2010 605 613
23. T. Uchida, T. Kinoshita, H. Nagai, Y. Nakahara, H. Saito, T. Hotta, and T. Murate Hypermethylation of the p15INK4B gene in myelodysplastic syndromes Blood 90 1997 1403 1409 (Pubitemid 27355412)
24. P. Wijermans, M. Lubbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, and A. Ferrant Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 2000 956 962 (Pubitemid 30123770)
25. H. Kantarjian, J.P. Issa, and C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
26. M. Tahiliani, K.P. Koh, and Y. Shen Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 2009 930 935
27. S. Ito, A.C. D'Alessio, O.V. Taranova, K. Hong, L.C. Sowers, and Y. Zhang Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification Nature 466 2010 1129 1133
28. F. Delhommeau, S. Dupont, and V. Della Valle Mutation in TET2 in myeloid cancers N Engl J Med 360 2009 2289 2301
29. S.M. Langemeijer, R.P. Kuiper, and M. Berends Acquired mutations in TET2 are common in myelodysplastic syndromes Nat Genet 41 2009 838 842
30. O. Kosmider, V. Gelsi-Boyer, and M. Cheok TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 114 2009 3285 3291
31. A.E. Smith, A.M. Mohamedali, and A. Kulasekararaj Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value Blood 116 2010 3923 3932
32. A. Tefferi, K.H. Lim, and O. Abdel-Wahab Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML Leukemia 23 2009 1343 1345
33. O. Nibourel, O. Kosmider, and M. Cheok Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission Blood 116 2010 1132 1135
34. O. Abdel-Wahab, T. Manshouri, and J. Patel Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias Cancer Res 70 2010 447 452
35. Y.S. Cho, E.J. Kim, U.H. Park, H.S. Sin, and S.J. Um Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor J Biol Chem 281 2006 17588 17598
36. J.C. Scheuermann, A.G. de Ayala Alonso, and K. Oktaba Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB Nature 465 2010 243 247
37. S.W. Lee, Y.S. Cho, J.M. Na, U.H. Park, M. Kang, E.J. Kim, and S.J. Um ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1 J Biol Chem 285 2010 18 29
38. C.L. Fisher, I. Lee, and S. Bloyer Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice Dev Biol 337 2010 9 15
39. C.L. Fisher, N. Pineault, and C. Brookes Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia Blood 115 2010 38 46
40. V. Gelsi-Boyer, V. Trouplin, and J. Adelaide Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia Br J Haematol 145 2009 788 800
41. J. Rocquain, N. Carbuccia, and V. Trouplin Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias BMC Cancer 10 2010 401
42. N. Carbuccia, A. Murati, and V. Trouplin Mutations of ASXL1 gene in myeloproliferative neoplasms Leukemia 23 2009 2183 2186
43. W.C. Chou, H.H. Huang, and H.A. Hou Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations Blood 116 2010 4086 4094
44. G. Nikoloski, S.M. Langemeijer, and R.P. Kuiper Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat Genet 42 2010 665 667
45. T. Ernst, A.J. Chase, and J. Score Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 42 2010 722 726
46. J.A. Simon, and C.A. Lange Roles of the EZH2 histone methyltransferase in cancer epigenetics Mutat Res 647 2008 21 29
47. H.J. Deeg, C. Beckham, and M.R. Loken Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome Leuk Lymphoma 37 2000 405 414 (Pubitemid 30162551)
48. A.M. Marcondes, A.J. Mhyre, D.L. Stirewalt, S.H. Kim, C.A. Dinarello, and H.J. Deeg Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function Proc Natl Acad Sci U S A 105 2008 2865 2870 (Pubitemid 351723635)
49. M.H. Raaijmakers, S. Mukherjee, and S. Guo Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia Nature 464 2010 852 857
50. E.M. Sloand, C.O. Wu, P. Greenberg, N. Young, and J. Barrett Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy J Clin Oncol 26 2008 2505 2511
51. D.P. Steensma Novel therapies for myelodysplastic syndromes Hematol Oncol Clin North Am 24 2010 423 441
52. M.T. Voso, V. Santini, and C. Finelli Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes Clin Cancer Res 15 2009 5002 5007
53. G. Garcia-Manero, S. Assouline, and J. Cortes Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 112 2008 981 989
54. R. Itzykson, S. Ayari, and D. Vassilief Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases Leukemia 23 2009 673 678
55. T. Fischer, R.M. Stone, and D.J. Deangelo Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 J Clin Oncol 28 2010 4339 4345
56. Y. Hitoshi, N. Lin, D.G. Payan, and V. Markovtsov The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases Int J Hematol 91 2010 189 200